Author

W.-H. Tang

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Research Focus:benchmarking· 1 Assay:protein structure· 1 Assay:proteomics· 1 Organism:rat· 1

Frequent Co-Authors

C. Chen· 3 shared C.-C. Wu· 3 shared M.-Y. Lin· 3 shared T.-Y. Kuo· 3 shared Y.-J. Lin· 3 shared J. Cheng· 2 shared J. D. Campbell· 2 shared L. T. C. Liu· 2 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

C. Chen

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Neutralization of SARS-CoV-2 Omicron BA.4/BA.5 subvariant by a booster dose of bivalent adjuvanted subunit vaccine containing Omicron BA.4/BA.5 and BA.1 subvariants

T.-Y. Kuo, C. E. Lien, Y.-J. Lin, M.-Y. Lin, L. T.-C. Liu, C.-C. Wu, W.-H. Tang, C. Chen

This study evaluates the effectiveness of a bivalent subunit vaccine containing Omicron BA.4/BA.5 and BA.1 subvariants as a booster, finding it provides the highest neutralizing titers against BA.4/BA.5 in mice.

bioRxiv · Oct 7, 2022 · PreprintImmunology

Protection of Hamsters Challenged with SARS-CoV-2 Variants of Concern by Two Doses of MVC-COV1901 Vaccine Followed by a Single Dose of Beta Variant Version of MVC-COV1901

T.-Y. Kuo, C.-E. Lien, Y.-J. Lin, M.-Y. Lin, C.-C. Wu, W.-H. Tang, J. D. Campbell, P. Traquina, Y.-S. Chuang, L. T. C. Liu, J. Cheng, C. Chen

This study evaluates the efficacy of a vaccine regimen using wildtype and Beta variant S-2P in hamsters against SARS-CoV-2 Delta and VoCs, showing improved neutralization and protection with a mixed-dose schedule.

bioRxiv · Sep 29, 2021 · PreprintImmunology

Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19

T.-Y. Kuo, M.-Y. Lin, R. L. Coffman, J. D. Campbell, P. Traquina, Y.-J. Lin, L. T. C. Liu, J. Cheng, Y.-C. Wu, C.-C. Wu, W.-H. Tang, C.-G. Huang, K.-C. Tsao, S.-R. Shih, C. Chen

This paper develops a subunit vaccine against COVID-19 using CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen and shows it induces high neutralizing antibody titers and Th1 response in mice.

bioRxiv · Aug 11, 2020Immunology